Aa
Tele, VX-222 and Riba for 12 weeks
No interferon? Niiiiice. 12 weeks of therapy only...........super duper niiiiice.
Hope it works then we will be remembering how once there wasn't even telepravir while waiting impatiently for this new triple to come out.
Vertex Announces Plans to Enroll Additional Treatment Arm in Ongoing Phase 2 Combination Study of Telaprevir and VX-222 for the Treatment of People with Hepatitis C
-New treatment arm to evaluate all oral, triple combination regimen of telaprevir, VX-222, and ribavirin-
CAMBRIDGE, Mass., Nov 10, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated /quotes/comstock/15*!vrtx/quotes/nls/vrtx (VRTX 33.47, -0.63, -1.85%) today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222. The planned treatment arm is supported by emerging data from multiple ongoing clinical trials of direct-acting antiviral (DAA) therapies, including the trial of telaprevir/VX-222-based combination therapy, which suggest that adding ribavirin to a DAA treatment regimen may increase antiviral activity. In the additional arm, Vertex plans to evaluate a 12-week combination of three oral therapies -- VX-222, telaprevir and ribavirin -- dosed twice a day within a response-guided regimen.
"We are encouraged by the high viral cure rates and shorter treatment durations reported in Phase 3 studies of telaprevir-based combination therapy, and we remain focused on continuing to develop new potential treatments for hepatitis C," said Robert Kauffman, M.D., Ph.D., Senior Vice President and Chief Medical Officer for Vertex. "Evaluating a 12-week combination of telaprevir, VX-222 and ribavirin will provide us with important information about the potential for this all-oral regimen that could be taken twice a day."
About the Ongoing Phase 2 Trial of Telaprevir and VX-222
Beginning in August 2010, patients enrolled in the randomized, parallel-group, dose-ranging Phase 2 trial started receiving treatment. The primary endpoint of this trial is to assess safety and tolerability of 12-week telaprevir/VX-222-based combination therapy in people with genotype 1 chronic hepatitis C. A secondary endpoint of this study is to assess on-treatment antiviral activity and the proportion of patients in each study arm who achieve a sustained viral response (SVR; defined as undetectable HCV RNA 24 weeks after the end of treatment). If patients meet response-guided criteria during treatment (undetectable HCV RNA at week 2 and week 8 of treatment), they may be eligible to stop all therapy at 12 weeks.
The study includes treatment arms that are evaluating 12-week, response-guided regimens of two- and four-drug telaprevir/VX-222 combination therapy, given twice daily, with and without Pegasys(R) (pegylated-interferon alfa-2a) and Copegus(R) (ribavirin). Trial sites for the two- and four-drug ongoing arms completed enrollment in October 2010. The additional three-drug treatment arm of telaprevir, VX-222 and ribavirin announced today is expected to begin patient enrollment in the first quarter of 2011, pending completion of institutional review board (IRB) approvals and consultation with regulatory agencies. Based on further results from the ongoing treatment arms, Vertex may add an additional arm in this study.
Additional Clinical Trial of VX-222 Combination Therapy
Vertex is also conducting a Phase 2 clinical trial evaluating the safety, tolerability and antiviral activity of VX-222 in combination with pegylated-interferon and ribavirin, which began in August 2010. Enrollment is ongoing and Vertex expects to enroll a total of 50 patients. Patients in this trial will receive one of two doses of VX-222 (400 mg or 750 mg twice daily) in combination with pegylated-interferon alfa-2a and ribavirin for 12 weeks, followed by pegylated-interferon alfa-2a and ribavirin alone for 36 weeks.
About Telaprevir and VX-222
Telaprevir is an investigational, oral inhibitor of HCV protease, an enzyme essential for viral replication, and is being developed by Vertex Pharmaceuticals in collaboration with Tibotec Pharmaceuticals and Mitsubishi Tanabe Pharma. Phase 3 studies of telaprevir in combination with pegylated interferon alfa-2a and ribavirin are complete and Vertex is on track to complete its rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration by the end of 2010.
VX-222 is an investigational, oral, non-nucleoside inhibitor of HCV NS5B polymerase. Vertex added VX-222 to its development pipeline as part of the acquisition of ViroChem Pharma Inc. in March 2009. Vertex retains worldwide commercial rights to VX-222.
About Hepatitis C
Hepatitis C is a liver disease caused by the hepatitis C virus, which is found in the liver and blood of people with the disease.(2) According to a 2010 report from the Institute of Medicine, up to 3.9 million people in the United States have chronic hepatitis C and 75% of those infected are unaware of their infection.(3)Approximately 60 percent of genotype 1 patients who undergo an initial 48-week regimen with pegylated-interferon and ribavirin, the currently approved treatment regimen, do not achieve SVR, (4,5,6)or viral cure.(1)
Hope it works then we will be remembering how once there wasn't even telepravir while waiting impatiently for this new triple to come out.
Vertex Announces Plans to Enroll Additional Treatment Arm in Ongoing Phase 2 Combination Study of Telaprevir and VX-222 for the Treatment of People with Hepatitis C
-New treatment arm to evaluate all oral, triple combination regimen of telaprevir, VX-222, and ribavirin-
CAMBRIDGE, Mass., Nov 10, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated /quotes/comstock/15*!vrtx/quotes/nls/vrtx (VRTX 33.47, -0.63, -1.85%) today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222. The planned treatment arm is supported by emerging data from multiple ongoing clinical trials of direct-acting antiviral (DAA) therapies, including the trial of telaprevir/VX-222-based combination therapy, which suggest that adding ribavirin to a DAA treatment regimen may increase antiviral activity. In the additional arm, Vertex plans to evaluate a 12-week combination of three oral therapies -- VX-222, telaprevir and ribavirin -- dosed twice a day within a response-guided regimen.
"We are encouraged by the high viral cure rates and shorter treatment durations reported in Phase 3 studies of telaprevir-based combination therapy, and we remain focused on continuing to develop new potential treatments for hepatitis C," said Robert Kauffman, M.D., Ph.D., Senior Vice President and Chief Medical Officer for Vertex. "Evaluating a 12-week combination of telaprevir, VX-222 and ribavirin will provide us with important information about the potential for this all-oral regimen that could be taken twice a day."
About the Ongoing Phase 2 Trial of Telaprevir and VX-222
Beginning in August 2010, patients enrolled in the randomized, parallel-group, dose-ranging Phase 2 trial started receiving treatment. The primary endpoint of this trial is to assess safety and tolerability of 12-week telaprevir/VX-222-based combination therapy in people with genotype 1 chronic hepatitis C. A secondary endpoint of this study is to assess on-treatment antiviral activity and the proportion of patients in each study arm who achieve a sustained viral response (SVR; defined as undetectable HCV RNA 24 weeks after the end of treatment). If patients meet response-guided criteria during treatment (undetectable HCV RNA at week 2 and week 8 of treatment), they may be eligible to stop all therapy at 12 weeks.
The study includes treatment arms that are evaluating 12-week, response-guided regimens of two- and four-drug telaprevir/VX-222 combination therapy, given twice daily, with and without Pegasys(R) (pegylated-interferon alfa-2a) and Copegus(R) (ribavirin). Trial sites for the two- and four-drug ongoing arms completed enrollment in October 2010. The additional three-drug treatment arm of telaprevir, VX-222 and ribavirin announced today is expected to begin patient enrollment in the first quarter of 2011, pending completion of institutional review board (IRB) approvals and consultation with regulatory agencies. Based on further results from the ongoing treatment arms, Vertex may add an additional arm in this study.
Additional Clinical Trial of VX-222 Combination Therapy
Vertex is also conducting a Phase 2 clinical trial evaluating the safety, tolerability and antiviral activity of VX-222 in combination with pegylated-interferon and ribavirin, which began in August 2010. Enrollment is ongoing and Vertex expects to enroll a total of 50 patients. Patients in this trial will receive one of two doses of VX-222 (400 mg or 750 mg twice daily) in combination with pegylated-interferon alfa-2a and ribavirin for 12 weeks, followed by pegylated-interferon alfa-2a and ribavirin alone for 36 weeks.
About Telaprevir and VX-222
Telaprevir is an investigational, oral inhibitor of HCV protease, an enzyme essential for viral replication, and is being developed by Vertex Pharmaceuticals in collaboration with Tibotec Pharmaceuticals and Mitsubishi Tanabe Pharma. Phase 3 studies of telaprevir in combination with pegylated interferon alfa-2a and ribavirin are complete and Vertex is on track to complete its rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration by the end of 2010.
VX-222 is an investigational, oral, non-nucleoside inhibitor of HCV NS5B polymerase. Vertex added VX-222 to its development pipeline as part of the acquisition of ViroChem Pharma Inc. in March 2009. Vertex retains worldwide commercial rights to VX-222.
About Hepatitis C
Hepatitis C is a liver disease caused by the hepatitis C virus, which is found in the liver and blood of people with the disease.(2) According to a 2010 report from the Institute of Medicine, up to 3.9 million people in the United States have chronic hepatitis C and 75% of those infected are unaware of their infection.(3)Approximately 60 percent of genotype 1 patients who undergo an initial 48-week regimen with pegylated-interferon and ribavirin, the currently approved treatment regimen, do not achieve SVR, (4,5,6)or viral cure.(1)
Forgot to say that it also has to do with what is going on with boceprevir. Those analysts watch those things closely and make their predictions and suggestions, in part, from that.
"I think this new trial is completely separate from the Telaprevir + SOC trial and won't have any impact one way or the other with the FDA process.
Vertex stock price is dependent on the analyst buy/sell.hold recommendations. I would look that up. Since the stock dropped recently, I bet an analyst downgraded it. It usually has no meaning at all except to Wall Street. "
............................................................
You have hit the nail on the head.
Vertex stock price is dependent on the analyst buy/sell.hold recommendations. I would look that up. Since the stock dropped recently, I bet an analyst downgraded it. It usually has no meaning at all except to Wall Street. "
............................................................
You have hit the nail on the head.
Any none interferon thing sounds great to me and for only 12 weeks......wow.
________ ________________________________________________________
Absolutely, I'll take an order with fries on the side. lol
________ ________________________________________________________
Absolutely, I'll take an order with fries on the side. lol
I think this new trial is completely separate from the Telaprevir + SOC trial and won't have any impact one way or the other with the FDA process.
Vertex stock price is dependent on the analyst buy/sell.hold recommendations. I would look that up. Since the stock dropped recently, I bet an analyst downgraded it. It usually has no meaning at all except to Wall Street.
Vertex stock price is dependent on the analyst buy/sell.hold recommendations. I would look that up. Since the stock dropped recently, I bet an analyst downgraded it. It usually has no meaning at all except to Wall Street.
I'm glad they are focused on the next big thing - if they have people actively working against each other in the company it will make them work even harder. Every single step is a big step. I'd imagine they have different people working on different things and it wouldn't hold up the FDA approval ............. I hope.
Any none interferon thing sounds great to me and for only 12 weeks......wow.
Any none interferon thing sounds great to me and for only 12 weeks......wow.
My guess is that Vrtx is continually focused on the 'next big thing'. First it's 950 and then the various permutations with 222. I think these guys are pretty sharp, evidenced by things like the Commerical Officer they brought on a year ago through the rmore recent Ambassador program. And, that's not considering ther non-HCV stuff.
Deb
This is good news BUT I wonder if it is extending the time before they send paperwork for FDA approval.. I don't have that on any authority, but their stock has dropped lately and it may be because of the possibility that it will take a lot longer until TEL hits the market.
Since these are only Phase II trials, combo'ed with VX-222, it seems to me that if they wait on this, it could be another year or two before they have the Phase III trials and the six months post results.
Anyone else see it that way? I mean, it would be lovely to drop the INF but how long is all of this going to take?
frijole
This is good news BUT I wonder if it is extending the time before they send paperwork for FDA approval.. I don't have that on any authority, but their stock has dropped lately and it may be because of the possibility that it will take a lot longer until TEL hits the market.
Since these are only Phase II trials, combo'ed with VX-222, it seems to me that if they wait on this, it could be another year or two before they have the Phase III trials and the six months post results.
Anyone else see it that way? I mean, it would be lovely to drop the INF but how long is all of this going to take?
frijole
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
